DISCOVER OUR PIONEERING CONTRIBUTIONS TO ONCOLOGY THROUGH PRESTIGIOUS JOURNALS AND PLATFORMS LIKE ASCO, ESMO, AND SABCS. ELEVATE YOUR INSIGHTS WITH OUR CUTTING-EDGE CLINICAL TRIAL PUBLICATIONS.
EMPOWERING PROGRESS: ONCOLOGY CLINICAL TRIALS SPOTLIGHT
PUBLICATIONS
THE ULTIMATE GOAL OF MEDSIR PROJECTS IS THE PUBLICATION OF ITS STUDY RESULTS, WHETHER IN PEER-REVIEWED JOURNALS OR AT A NUMBER OF NATIONAL AND INTERNATIONAL CONFERENCES IN THE FORM OF ABSTRACTS, POSTERS, OR ORAL PRESENTATIONS.
STUDY
OFFICIAL TITLE
DISEASE
JOURNAL/
CONGRESS
YEAR
DOWNLOAD
PARSIFAL
PD13-10 – Impact of Proton Pump Inhibitors (PPI) on Palbociclib (PAL) Outcomes in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer (HR+/HER2-ABC): Exploratory Analysis of the PARSIFAL Trial
BREAST
SABCS
2022
COPERNICO
Pembrolizumab in combination with tocilizumab in high-risk hospitalized patients with COVID-19 (COPERNICO): A randomized proof-of-concept phase II study
COVID-19
(Journal) International Journal of Infectious Disease
2022
ATRACTIB
ATRACTIB: A Phase 2 Trial of First-Line (1L) Atezolizumab (A) in Combination with Paclitaxel (P) and Bevacizumab (B) in Metastatic Triple-Negative Breast Cancer (mTNBC)
BREAST
ESMO Breast
2022
OPHELIA
Olaparib plus Trastuzumab in HER2[+] BRCA-Mutated Advancewd Breast Cancer Patients: The OPHELIA Study.
BREAST
SABCS
2022
DEBBRAH
Trastuzumab deruxtecan (T-DXd; DS-8201) en pacientes con cáncer de mama metastásico HER2-positivo o con baja expresión de HER2 con metástasis cerebrales y/o carcinomatosis leptomeníngea: Estudio DEBBRAH
BREAST
SEOM
2021
PATHFINDER
Ipatasertib plus non-taxane chemotherapy for metastatic triple-negative breast cancer: Pathfinder trial
BREAST
ESMO
2021
DEBBRAH
Trastuzumab Deruxtecan (DS-8201) in HER2-Positive and HER2-Low Expressing Metastatic Breast Cancer with Brain Metastases and/or Leptomeningeal Carcinomatosis: DEBBRAH
BREAST
ESMO
2021
OTHER
I-SPY2 platform: New lessons from the olaparib and durvalumab combination in breast cancer treatment
BREAST
(Journal) Cancer Cell
2021
LINGAIN
Analysis of αβ and γδ circulating T cells in the PHERGain randomized phase 2 trial for patients with HER2-positive early breast cancer receiving neoadjuvant trastuzumab and pertuzumab without chemotherapy: LINGain
BREAST
SABCS
2021
ABIGAIL
Phase 2 study of abemaciclib in combination with endocrine therapy with or without paclitaxel induction in patients with hormone receptor-positive, HER2-negative advanced breast cancer and aggressive disease criteria: ABIGAIL
BREAST
SABCS
2021
COPERNICO
Tocilizumab (T) plus pembrolizumab (P) in patients (pts) with Covid-19 pneumonia: COPERNICO
COVID-19
(Journal) ERS International Congress
2021
DXCARTES
Neoadjuvant letrozole plus palbociclib in patients with hormone receptor positive/HER2-negative breast cancer with baseline Ki67>20% and an Oncotype DX recurrence score* result >18: DXCARTES
BREAST
SABCS
2021
Other MEDSIR related articles
